{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T21:06:09Z","timestamp":1772485569947,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jhepr.2025.101568","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:28:23Z","timestamp":1759552103000},"page":"101568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2330-0017","authenticated-orcid":false,"given":"Mattias","family":"Mandorfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-166X","authenticated-orcid":false,"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101568_bib1","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101568_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101568_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cld.2021.01.003","article-title":"Prevention of first decompensation in advanced chronic liver disease","volume":"25","author":"Mandorfer","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101568_bib4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2023.12.028","article-title":"Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient","volume":"80","author":"Jachs","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101568_bib5","article-title":"Non-invasive assessment of portal hypertension: liver stiffness and beyond","volume":"7","author":"Mandorfer","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101568_bib6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S2468-1253(24)00234-6","article-title":"Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study","volume":"9","author":"Jachs","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101568_bib7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jhep.2022.08.025","article-title":"Non-invasive tests for clinically significant portal hypertension after HCV cure","volume":"77","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101568_bib8","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1111\/liv.15058","article-title":"Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease","volume":"41","author":"Broquetas","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101568_bib9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101568_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/HEP.0000000000001005","article-title":"Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure","volume":"81","author":"Semmler","year":"2024","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925002502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925002502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:34:09Z","timestamp":1772483649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925002502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2589555925002502"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101568","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101568"}}